3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sezary Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoma
1
Liposarcoma, Myxoid
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Hodgkin Disease
1
HIV Infections
1
Graft vs Host Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Brain Neoplasms
1
Acquired Immunodeficiency Syndrome
1
Interventions
ponatinib
2
pembrolizumab
2
napabucasin
2
ficlatuzumab
2
entinostat
2
Gemcitabine
2
Bortezomib
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
tetulomab tetraxetan lu-177
1
siltuximab
1
ruxolitinib
1
pralsetinib
1
pamiparib
1
nirogacestat
1
interferon gamma-1b
1
denileukin diftitox
1
bosutinib
1
blinatumomab
1
Vorinostat
1
Trabectedin
1
Radiation
1
Oncolytic Virotherapy
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Interferon-gamma
1
Immunotherapy
1
Imatinib Mesylate
1
HhAntag691
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms by Histologic Type
×
interferon gamma-1b
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled